Trial Profile
A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2014
Price :
$35
*
At a glance
- Drugs Anidulafungin (Primary) ; Voriconazole (Primary) ; Voriconazole (Primary)
- Indications Aspergillosis; Invasive bronchopulmonary aspergillosis
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
- 17 Apr 2014 New trial record
- 10 May 2012